About: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days
Creator	Takesue, Yoshio Ichiki, Kaoru Ikeuchi, Hiroki Ishihara, Mika Ishikawa, Kaori Kimura, Takeshi Nakajima, Kazuhiko Otani, Naruhito Takahashi, Yoshiko Takai, Yoshiko Takubo, Shingo Tsuchida, Toshie Uchino, Motoi Ueda, Takashi Yamada, Kumiko
Source	PMC
abstract	BACKGROUND: A trough concentration (C(min)) ≥20 μg/mL of teicoplanin is recommended for the treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections. However, sufficient clinical evidence to support the efficacy of this target C(min) has not been obtained. Even though the recommended high C(min) of teicoplanin was associated with better clinical outcome, reaching the target concentration is challenging. METHODS: Pharmacokinetics and adverse events were evaluated in all eligible patients. For clinical efficacy, patients who had bacteremia/complicated MRSA infections were analyzed. The primary endpoint for clinical efficacy was an early clinical response at 72–96 h after the start of therapy. Five dosed of 12 mg/kg or 10 mg/kg was administered as an enhanced or conventional high loading dose regimen, respectively. The C(min) was obtained at 72 h after the first dose. RESULTS: Overall, 512 patients were eligible, and 76 patients were analyzed for treatment efficacy. The proportion of patients achieving the target C(min) range (20–40 μg/mL) by the enhanced regimen was significantly higher than for the conventional regimen (75.2% versus 41.0%, p < 0.001). In multivariate analysis, C(min) ≥ 20 μg/mL was an independent factor for an early clinical response (odds ratio 3.95, 95% confidence interval 1.25–12.53). There was no significant difference in the occurrence of adverse events between patients who did or did not achieve a C(min) ≥ 20 μg/mL. CONCLUSION: A target C(min) ≥ 20 μg/mL might improve early clinical responses during the treatment of difficult MRSA infections using 12 mg/kg teicoplanin for five doses within the initial 3 days.
has issue date	2020-07-08(xsd:dateTime)
bibo:doi	10.1186/s40360-020-00424-3
has license	cc-by
sha1sum (hex)	8dc942b1e699c1f3538b2e4a6a8df723b8dc2486
schema:url	https://doi.org/10.1186/s40360-020-00424-3
resource representing a document's title	Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days
has PubMed Central identifier	PMC7341468
schema:publication	BMC Pharmacol Toxicol
resource representing a document's body	covid:8dc942b1e699c1f3538b2e4a6a8df723b8dc2486#body_text
is schema:about of	named entity 'infections' named entity 'teicoplanin' named entity 'Clinical' named entity 'TO SUPPORT' covid:arg/8dc942b1e699c1f3538b2e4a6a8df723b8dc2486 named entity 'methicillin-resistant Staphylococcus aureus (MRSA)' named entity 'teicoplanin' named entity 'high C' named entity 'clinical evidence' named entity 'initial' named entity 'MRSA' named entity 'loading dose' named entity 'eGFR' named entity 'significant difference' named entity 'teicoplanin' named entity 'antibiotics' named entity 'teicoplanin' named entity 'adverse events' named entity 'renal function' named entity 'teicoplanin' named entity '28 days' named entity 'infection' named entity 'MIC' named entity 'joint infections' named entity 'European Committee on Antimicrobial Susceptibility Testing' named entity 'renal function' named entity 'maintenance dose' named entity 'alanine aminotransferase' named entity 'loading dose' named entity 'loading dose' named entity 'infection' named entity 'clinical setting' named entity 'loading dose' named entity 'multivariate analysis' named entity 'body weight' named entity 'primary endpoint' named entity 'loading dose' named entity 'hepatotoxicity' named entity 'multivariate analyses' named entity 'minimum inhibitory concentration' named entity 'teicoplanin' named entity 'MRSA' named entity 'Institutional Review Board' named entity 'MRSA' named entity 'Hepatotoxicity' named entity 'AUC' named entity 'total parenteral nutrition' named entity 'steady state' named entity 'Tokyo' named entity 'joint infections' named entity 'VAP' named entity 'Serum albumin' named entity 'infection' named entity '18.3' named entity 'high levels' named entity 'loading dose' named entity 'United States' named entity 'teicoplanin' named entity '18.2' named entity 'loading dose' named entity 'multivariate analysis' named entity 'eGFR' named entity 'loading dose' named entity 'steady state' named entity 'maintenance dose' named entity 'cell death' named entity 'MRSA' named entity 'loading dose' named entity 'pathogen'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software